The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides
Open accessAbstract
Multidrug resistance (MDR) is a major impediment to chemotherapy. In the present study, we designed antisense oligonucleotides (ASOs) against MDR1, MDR-associated protein (MRP)1, MRP2, and/or BCL-2/BCL-xL to reverse MDR transporters and induce apoptosis, respectively. The cationic liposomes (100 nm) composed of N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride and dioleoyl phosphotidylethanolamine core surrounded by a polyethylene glycol (PEG) shell were prepared to carry ASOs and/or epirubicin, an antineoplastic agent. We aimed to simultaneously suppress efflux pumps, provoke apoptosis, and enhance the chemosensitivity of human colon adenocarcinoma Caco-2 cells to epirubicin. We evaluated encapsulation efficiency, particle size, cytotoxicity, intracellular accumulation, mRNA levels, cell cycle distribution, and caspase activity of these formulations. We found that PEGylated liposomal ASOs significantly reduced Caco-2 cell viability and thus intensified epirubicin-mediated apoptosis. These formulations also decreased the MDR1 promoter activity levels and enhanced the intracellular retention of epirubicin in Caco-2 cells. Epirubicin and ASOs in PEGylated liposomes remarkably decreased mRNA expression levels of human MDR1, MRP1, MRP2, and BCL-2. The combined treatments all significantly increased the mRNA expressions of p53 and BAX, and activity levels of caspase-3, -8, and -9. The formulation of epirubicin and ASOs targeting both pump resistance of MDR1, MRP1, and MRP2 and nonpump resistance of BCL-2/BCL-xL demonstrated more superior effect to all the other formulations used in this study. Our results provide a novel insight into the mechanisms by which PEGylated liposomal ASOs against both resistance types act as activators to epirubicin-induced apoptosis through suppressing MDR1, MRP1, and MRP2, as well as triggering intrinsic mitochondrial and extrinsic death receptor pathways. The complicated regulation of MDR highlights the necessity for a multifunctional approach using an effective delivery system, such as PEGylated liposomes, to carry epirubicin and ASOs as a potent nanomedicine for improving the clinical efficacy of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, liposome AOSs reverse multi-drug resistance in vivo and in vitro by inhibiting the expression of P-GP, MRP1, MRP2 and Bcl-2/Bcl-XL, which may enhance the sensitivity of CRC to chemotherapy by decreasing the activity level of the MDR1 promoter [15,16].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 791
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Taipalensuu, J., Törnblom, H., Lindberg, G., Einarsson, C., Sjöqvist, F., Melhus, H., Garberg, P., Sjöström, B., Lundgren, B., & Artursson, P. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29314-9 · Cited by 444
An overview of cancer multidrug resistance: a still unsolved problem
Lage, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8111-5 · Cited by 408
Multiple roles of the tumor suppressor p53
Bargonetti, J., & Manfredi, J. J. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200201000-00015 · Cited by 332
Transcriptional regulation by the Sp family proteins
Lania, L., Majello, B., & de Luca, P. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(97)00094-0 · Cited by 285
Li, S.-D., & Huang, L. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060039w · Cited by 282
Antisense oligonucleotide-based therapeutics for cancer
Dean, N. M., & Bennett, C. F. (2003) · Oncogene · doi:10.1038/sj.onc.1207231 · Cited by 234
Lo, Y.-L. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00163-9 · Cited by 233
Self-citationPlosker, G. L., & Faulds, D. (1993) · Drugs · doi:10.2165/00003495-199345050-00011 · Cited by 223
Makhey, V. D., Guo, A., Norris, D. A., Hu, P., Yan, J., & Sinko, P. J. (1998) · Pharmaceutical Research · doi:10.1023/a:1011971303880 · Cited by 215
Molecular Targeting of Drug Delivery Systems to Cancer
Minko, T., Dharap, S., Pakunlu, R., & Wang, Y. (2004) · Current Drug Targets · doi:10.2174/1389450043345443 · Cited by 175
First "Antisense" Drug Will Treat CMV Retinitis
Marwick, C. (1998) · JAMA · doi:10.1001/jama.280.10.871-jmn0909-6-1 · Cited by 167
Minko, T., Batrakova, E. V., Li, S., Li, Y., Pakunlu, R. I., Alakhov, V. Y., & Kabanov, A. V. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.019 · Cited by 151
Buchholz, T. A., Davis, D. W., McConkey, D. J., Symmans, W. F., Valero, V., Jhingran, A., Tucker, S. L., Pusztai, L., Cristofanilli, M., Esteva, F. J., et al. (2003) · The Cancer Journal · doi:10.1097/00130404-200301000-00007 · Cited by 142
Pakunlu, R. I., Wang, Y., Saad, M., Khandare, J. J., Starovoytov, V., & Minko, T. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.06.010 · Cited by 134
Nakagawa, O., Ming, X., Huang, L., & Juliano, R. L. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102635c · Cited by 120
Zhang, W., Shi, Y., Chen, Y., Hao, J., Sha, X., & Fang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.075 · Cited by 112
Ray, R. M., Bhattacharya, S., & Johnson, L. R. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0538-0 · Cited by 108
Yamanaka, K., Rocchi, P., Miyake, H., Fazli, L., Vessella, B., Zangemeister‐Wittke, U., & Gleave, M. E. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0064 · Cited by 101
Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells
Daschner, P. J., Ciolino, H. P., Plouzek, C. A., & Yeh, G. C. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006138803392 · Cited by 94
Takane, H., Kobayashi, D., Hirota, T., Kigawa, J., Terakawa, N., Otsubo, K., & Ieiri, I. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.069724 · Cited by 90
Ruefli, A. A., Tainton, K. M., Darcy, P. K., Smyth, M. J., & Johnstone, R. W. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401081 · Cited by 76
Liposome clearance from blood: different animal species have different mechanisms
Liu, D., Hu, Q., & Song, Y. K. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00184-0 · Cited by 73
Miao, Z., Tang, T., Zhang, Y., Zhang, J., & Ding, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11174 · Cited by 71
Marbeuf‐Gueye, C., Salerno, M., Quidu, P., & Garnier‐Suillerot, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00047-9 · Cited by 64
Yamanaka, K., Rocchi, P., Miyake, H., Fazli, L., So, A., Zangemeister‐Wittke, U., & Gleave, M. E. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06147.x · Cited by 63
Harada, T., Ogura, S., Yamazaki, K., Kinoshita, I., Itoh, T., Isobe, H., Yamashiro, K., Dosaka‐Akita, H., & Nishimura, M. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01453.x · Cited by 61
Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin
Lo, Y., Ho, C., & Tsai, F. L. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.06.003 · Cited by 55
Self-citationTumor chemosensitization strategies based on apoptosis manipulations.
Shabbits, J. A., Hu, Y., & Mayer, L. D. (2003) · PubMed · Cited by 55
ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer
Balcerczak, E. I., Pańczyk, M., Piaskowski, S., Pasz‐Walczak, G., Sałagacka-Kubiak, A., & Mirowski, M. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-010-0961-2 · Cited by 52
Synthesis and Formulation of Neoglycolipids for the Functionalization of Liposomes and Lipoplexes
Pérouzel, É., Jorgensen, M. R., Keller, M., & Miller, A. D. (2003) · Bioconjugate Chemistry · doi:10.1021/bc034068q · Cited by 51
Lo, Y., Wang, W., & Ho, C. (2012) · Toxicology · doi:10.1016/j.tox.2012.08.003 · Cited by 45
Self-citationZhou, L., He, X., Yu, J., Zhou, R., Shan, Y., & Rui, J. (2011) · Surgery · doi:10.1016/j.surg.2010.12.010 · Cited by 36
Lo, Y. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010158 · Cited by 35
Self-citationABCB1/MDR1 gene polymorphism and colorectal cancer risk: a meta‐analysis of case–control studies
He, T., Mo, A., Zhang, K., & Liu, L. (2012) · Colorectal Disease · doi:10.1111/j.1463-1318.2012.02919.x · Cited by 33
Lü, W.-L., Men, Wang, Li, Zhang, Tian, Yao, Ju, R.-J., Ying, Zhou, et al. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s24847 · Cited by 30
Campone, M., Vavasseur, F., Cabellec, M. L., Méflah, K., Vallette, F. M., & Oliver, L. (2001) · Leukemia · doi:10.1038/sj.leu.2402222 · Cited by 30
Epirubicin in colorectal cancer
Holdener, E. E., Hansen, H. H., Høst, H., Bruntsch, U., Cavalli, F., Renard, J., Pinedo, H. M., & Rozencweig, M. (1985) · Investigational New Drugs · doi:10.1007/bf00176826 · Cited by 27
Lo, Y.-L., Liu, Y., & Tsai, J.-C. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2012.12.002 · Cited by 26
Self-citationWang, X., Wang, C., Qin, Y., Yan, S.-K., & Gao, Y. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.09.001 · Cited by 22
Antisense-based cancer therapeutics: are we there yet?
Rayburn, E. R., Wang, H., & Zhang, R. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.2.337 · Cited by 15
Altundağ, K., Altundağ, Ö., Gündüz, M., & Arun, B. K. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.03.026 · Cited by 8
Cited by
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer
Chaiswing, L., Clair, W. H. S., & Clair, D. K. S. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7485 · Cited by 158
“It is noteworthy that at a lower dose, ROS increased MDR1 expression in Caco-2 colon cancer whereas at higher doses, ROS negatively regulated the MDR1 expression (204).”
BackgroundMulti drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
Ashique, S., Bhowmick, M., Pal, R., Khatoon, H., Kumar, P., Sharma, H., Garg, A., Kumar, S., & Das, U. (2024) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2024.100114 · Cited by 178
Metadata
- Authors
- Lo, Y.-L., & Liu, Y.
- Affiliations
- National University of Tainan (TW)
- Corresponding author
- Lo, Yu-Li
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-17
- Volume
- 9
- Issue
- 3
- Pages
- e90180
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3956467
- OpenAlex
- W1977619659
- Cited by
- 45
- References
- 44
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 7 · 2015: 4 · 2014: 4
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-11-04)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Science Council (NSC 102-2320-B-024-002)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- multidrug resistance, PEGylated liposomes, antisense oligonucleotides, MDR1, MRP1, MRP2, Bcl-2, Bcl-xL, epirubicin, Caco-2 cells, colon adenocarcinoma, apoptosis, efflux pump inhibition, chemosensitization, p53, Bax
- MeSH terms
- Multidrug Resistance-Associated Protein 2, Cell Cycle, Humans, Liposomes, Polyethylene Glycols, Promoter Regions, Genetic, RNA, Messenger, Epirubicin, Gene Expression, Gene Expression Regulation, Neoplastic, Oligonucleotides, Antisense, Apoptosis, Genes, Reporter, Caco-2 Cells, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, ATP Binding Cassette Transporter, Subfamily B, Member 1, Caspases, Gene Silencing, ATP-Binding Cassette, Sub-Family C Proteins, bcl-X Protein, DNA Fragmentation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.